Skip to content

Vibrating mesh nebulizer versus jet nebulizer in severe asthma exacerbation patients: A randomized controlled trial

Vibrating mesh nebulizer versus jet nebulizer in severe asthma exacerbation patients: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260720001
Enrollment
50
Registered
2026-07-20
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe asthma exacerbation severe asthma exacerbation, vibrating mesh nebulizer, aerogen

Interventions

Patient severe asthma exacerbation patient in ED Intervention prospective randomized open label parallel group-controlled trial Vibrating mesh nebulizer Comparison Jet nebulizer Outcome percentage
Jet nebulizer,Vibrating mesh nebulizer

Sponsors

Routine To Research Unit (R2R)
Lead Sponsor
Aerogen Ltd
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adults patients (age 18 years old and above) presenting with acute asthma exacerbation diagnosed by ED physician characterized by a progressive increase in shortness of breath, cough, wheezing or chest tightness1,2 2. Severe asthma exacerbation by meeting one of the following criteria a. Speak in phrase or lean forward or agitation b. Respiratory rate >30 breaths/min c. Accessory muscle used d. Pulse rate > 120 beats/min e. Room air oxygen saturation <90% f. Peak expiratory flow rate (PEFR) or FEV1 <50% of predicted or best value

Exclusion criteria

Exclusion criteria: 1.Documented diagnosis of asthma COPD overlap syndrome ACOS or bronchiectasis. 2.Respiratory failure requiring endotracheal intubation including any of the following: -Altered mental status -Severe air hunger -Cyanosis -Abdominal paradox -Progressive respiratory acidosis -Oxygen saturation less than 90 despite oxygen therapy by face mask -Cardiopulmonary arrest 3.Pulmonary edema on chest radiograph. 4.Requirement for high flow nasal cannula HFNC or non invasive ventilation NIV within the first hour after treatment initiation. 5.Unable to cooperate with pulmonary function testing. 6.Unable to provide written informed consent or declined study participation. 7.Pregnancy.

Design outcomes

Primary

MeasureTime frame
FEV1 at initial and 1 hour after intervention percentage change in FEV1

Secondary

MeasureTime frame
PEFR, FEV1 at initial and 1,2,4 hours after intervention percentage change of PEFR, FEV1,modified borg dyspnea scale at initial and 1,2,4 hours after intervention modified borg dyspnea scale,respiratory support 24 hours after intervention HFNC (high flow nasal cannula), NIV (non-invasive ventilation) ,endotracheal intubation,ED length of stay ED discharge hour of ED stay,hospital length of stay end of hospital stay day of hospital stay,bronchodilator ED discharge dose of bronchodilator,cost analysis end of hospital stay total treatment cost

Countries

Thailand

Contacts

Public ContactNattakarn Praphruetkit

Faculty of Medicine Siriraj Hospital

nattakarn107@yahoo.com024199216

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026